RESUMO
Due to its severe burden and geographic distribution, Chagas disease (CD) has a significant social and economic impact on low-income countries. Benznidazole and nifurtimox are currently the only drugs available for CD. These are prodrugs activated by reducing the nitro group, a reaction catalyzed by nitroreductase type I enzyme from Trypanosoma cruzi (TcNTR), with no homolog in the human host. The three-dimensional structure of TcNTR, and the molecular and chemical bases of the selective activation of nitro drugs, are still unknown. To understand the role of TcNTR in the basic parasite biology, investigate its potential as a drug target, and contribute to the fight against neglected tropical diseases, a combined approach using multiple biophysical and biochemical methods together with in silico studies was employed in the characterization of TcNTR. For the first time, the interaction of TcNTR with membranes was demonstrated, with a preference for those containing cardiolipin, a unique dimeric phospholipid that exists almost exclusively in the inner mitochondrial membrane in eukaryotic cells. Prediction of TcNTR's 3D structure suggests that a 23-residue long insertion (199 to 222), absent in the homologous bacterial protein and identified as conserved in protozoan sequences, mediates enzyme specificity, and is involved in protein-membrane interaction.
Assuntos
Doença de Chagas , Nitroimidazóis , Pró-Fármacos , Tripanossomicidas , Trypanosoma cruzi , Humanos , Nitroimidazóis/metabolismo , Nitroimidazóis/uso terapêutico , Nifurtimox/uso terapêutico , Doença de Chagas/tratamento farmacológico , Doença de Chagas/parasitologia , Nitrorredutases/química , Pró-Fármacos/uso terapêutico , Tripanossomicidas/químicaRESUMO
RESUMEN Introducción. La resistencia al metronidazol es un factor clave relacionado con el fracaso del tratamiento contra la infección por Helicobacter pylori asociada, principalmente, con mutaciones en la nitrorreductasa RdxA. A pesar de su importancia, los estudios sobre esta proteína son aún incipientes en Popayán, Colombia. Objetivo. Evaluar la frecuencia de las mutaciones en la nitrorreductasa RdxA en una población de pacientes con enfermedad gastrointestinal por H. pylori. Materiales y métodos. El ADN de 170 biopsias gástricas se amplificó mediante reacción en cadena de la polimerasa (PCR) para detectar las mutaciones en la nitrorreductasa RdxA. Se analizaron las secuencias traducidas a aminoácidos y se compararon con la cepa de referencia 26695. Resultados. La frecuencia de mutaciones de la nitrorreductasa RdxA en la población de estudio fue de 78 %. Su distribución más frecuente se detectó en las posiciones D59N (en 153 muestras), R131K (en 101 muestras), R90K (en 97 muestras), A118T (en 42 muestras), I160F (en 32 muestras), H97T (en 26 muestras) y en los codones de parada Q50*; D59*; E75*; C159* y I160* en cinco, una, tres, diez y seis muestras, respectivamente. El genotipo de virulencia más frecuente fue el vacAs1/m1 negativo para cagA (48,6 %). Conclusiones. La gran frecuencia de mutaciones en la nitrorreductasa RdxA en aislamientos de H. pylori en Popayán sugiere que los tratamientos empíricos con metronidazol no serían una opción válida para su erradicación en pacientes de la población estudiada.
ABSTRACT Introduction: Resistance to metronidazole is a key factor associated with Helicobacter pylori treatment failure. Even though resistance is mostly associated with RdxA nitroreductase mutations, studies of this H. pylori protein in Popayán (Colombia) are still incipient. Objective: To evaluate the frequency of mutations in the RdxA nitroreductase in a population of patients with H. pylori-positive gastrointestinal disease. Materials and methods: We amplified the DNA of 170 gastric biopsies by PCR to detect mutations in the RdxA nitroreductase. An analysis of DNA sequences translated into amino acid sequences was done and then compared to the reference strain 26695. Results: The frequency of RdxA nitroreductase mutations in this study population was 78%. Its most frequent distribution was found in positions D59N (153 samples), R131K (101 samples), R90K (97 samples), A118T (42 samples), I160F (32 samples) and H97T (26 samples), and meaningful stop codons Q50*, D59*; E75*, C159* and I160* in five, one, three, ten and six samples, respectively. The most common virulence genotype was vacAs1/m1 cagA negative (48.6 %). Conclusions: The high frequency of RdxA nitroreductase mutations in H. pylori isolates in Popayán (Colombia) indicates that empirical therapy with metronidazole may not be a valid option for the eradication of H. pylori in patients of the studied population.
Assuntos
Humanos , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Nitrorredutases/genética , Reação em Cadeia da Polimerase/métodos , Helicobacter pylori/genética , Metronidazol/farmacologia , Antibacterianos/farmacologia , Proteínas de Bactérias/química , Nitrorredutases/metabolismo , Nitrorredutases/química , Testes de Sensibilidade Microbiana , Helicobacter pylori/metabolismo , Colômbia , Genótipo , Metronidazol/química , Antibacterianos/química , MutaçãoRESUMO
INTRODUCTION: Resistance to metronidazole is a key factor associated with Helicobacter pylori treatment failure. Even though resistance is mostly associated with RdxA nitroreductase mutations, studies of this H. pylori protein in Popayán (Colombia) are still incipient. OBJECTIVE: To evaluate the frequency of mutations in the RdxA nitroreductase in a population of patients with H. pylori-positive gastrointestinal disease. MATERIALS AND METHODS: We amplified the DNA of 170 gastric biopsies by PCR to detect mutations in the RdxA nitroreductase. An analysis of DNA sequences translated into amino acid sequences was done and then compared to the reference strain 26695. RESULTS: The frequency of RdxA nitroreductase mutations in this study population was 78%. Its most frequent distribution was found in positions D59N (153 samples), R131K (101 samples), R90K (97 samples), A118T (42 samples), I160F (32 samples) and H97T (26 samples), and meaningful stop codons Q50*, D59*; E75*, C159* and I160* in five, one, three, ten and six samples, respectively. The most common virulence genotype was vacAs1/m1 cagA negative (48.6 %). CONCLUSIONS: The high frequency of RdxA nitroreductase mutations in H. pylori isolates in Popayán (Colombia) indicates that empirical therapy with metronidazole may not be a valid option for the eradication of H. pylori in patients of the studied population.
Assuntos
Antibacterianos/farmacologia , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Helicobacter pylori/genética , Metronidazol/farmacologia , Nitrorredutases/genética , Reação em Cadeia da Polimerase/métodos , Antibacterianos/química , Proteínas de Bactérias/química , Colômbia , Genótipo , Helicobacter pylori/metabolismo , Humanos , Metronidazol/química , Testes de Sensibilidade Microbiana , Mutação , Nitrorredutases/química , Nitrorredutases/metabolismoRESUMO
The nitroreductase family comprises a group of FMN- or FAD-dependent and NAD(P)H-dependent enzymes able to metabolize nitrosubstituted compounds. The nitroreductases are found within bacterial and some eukaryotic species. In eukaryotes, there is little information concerning the phylogenetic position and biochemical functions of nitroreductases. The yeast Saccharomyces cerevisiae has two nitroreductase proteins: Frm2p and Hbn1p. While Frm2p acts in lipid signaling pathway, the function of Hbn1p is unknown. In order to elucidate the function of Frm2p/Hbn1p and the presence of homologous sequences in other prokaryotic and eukaryotic species, we performed an in-depth phylogenetic analysis of these proteins. The results showed that bacterial cells have Frm2p/Hbn1p-like sequences (termed NrlAp) forming a distinct clade within the fungal Frm2p/Hbn1p family. Hydrophobic cluster analysis and three-dimensional protein modeling allowed us to compare conserved regions among NrlAp and Frm2/Hbn1p proteins. In addition, the possible functions of bacterial NrlAp and fungal Frm2p/Hbn1p are discussed.